Collateral for a security interest recorded Apr 27, 2026 (Citibank, N.A.).
Surrendered on reissue May 16, 2023 · Medium confidence
20-year base term ends Dec 18, 2035
Why Medium: No fee event states this; the fee state is read from the payments the fee record holds.
Surrendered on reissue May 16, 2023 · its term and maintenance fees continue in US RE49,529.
Held by Biomarin Pharmaceutical Inc.
Filed Jun 16, 2017 as application 15/536,880 · Granted Dec 3, 2019
Base term, 20 years from filing
Today
Surrendered May 16, 2023
2015
2035
Clock starts
Dec 18, 2015
Dec 18, 2015
No longer in force
May 16, 2023
May 16, 2023
Granted
Dec 3, 2019
Dec 3, 2019
Term would have run to
Dec 18, 2035
Dec 18, 2035
base term
after the term ends
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
Not on record
Maintenance fees
USPTO's record of this patent carries no fee events. A gap in the record, not evidence of lapse.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. USPTO's record of this patent carries no fee events, so no fee is counted as paid or unpaid. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 18, 2015, when application PCT/US2015/066646, the earliest non-provisional in its chain, was filed (this one was filed Jun 16, 2017) | Dec 18, 2035 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | No fee events in USPTO's record of this patent. A gap in the record, not evidence of lapse | no change | Medium confidence |
| Reissue | US RE49,529 issued May 16, 2023, and this patent's term continues in it (35 U.S.C. 251, 252) | surrendered May 16, 2023 | High confidence |
| Surrendered on reissue | The steps above, in order | May 16, 2023 | Medium confidence |
This family
| Application PCT/US2015/066646 | PCT application no patent term | no patent term |
| US 10,493,135 | this patent May 2023 | May 2023 |
| US RE49,529 | In force Dec 2035 | Dec 2035 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 14, 2017 Reel 43009, frame 544 | Quin, Anthony; Hsia, Nelson; Khan, Tayeba; Askew, Kim Lynnette; Grabowski, Gregory; Cheng, Zhiliang; O'neill, Charles | Alexion Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Aug 1, 2017 Reel 43400, frame 614 | Quin, Anthony; Hsia, Nelson; Khan, Tayeba; Askew, Kim Lynette; Grabowski, Gregory; Cheng, Zhiliang; O'neill, W. Charles | Alexion Pharmaceuticals, Inc. | Corrective Assignment to Correct the Spelling of the Seventh Assignor's Name Previously Recorded on Reel 043009 Frame 0544. Assignor(S) Hereby Confirms the Assignment. |
| Nov 23, 2020 Reel 54449, frame 251 | Alexion Pharmaceuticals, Inc. | Inozyme Pharma, Inc. | Assignment of Assignor's Interest |
| Nov 25, 2025 Reel 73707, frame 488 | Inozyme Pharma, Inc. | Biomarin Pharmaceutical Inc. | Assignment of Assignor's Interest |
| Apr 27, 2026 Reel 75493, frame 968 | Biomarin Pharmaceutical Inc.; Amicus Therapeutics, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Citations
7
later US patents cite this one
That is above the median of utility patents granted in 2019 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.